Novavax's Covid-19 Vaccine Cleared For Use In New Zealanders Aged 12-17

• New Zealand's Medsafe has granted expanded provisional approval for Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in adolescents aged 12 through 17.

• The provisional approval was based on data from the ongoing pediatric expansion of the Phase 3 PREVENT-19 trial of 2,247 adolescents aged 12 through 17.

• In the pediatric expansion, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% overall clinical efficacy when the Delta variant was predominant.

• Related Content: Novavax Seeks FDA Emergency Use Nod For Its COVID-19 Vaccine Booster.

• Preliminary safety data from the pediatric expansion showed the vaccine to be generally well-tolerated.

• There was no increase in reactogenicity in younger (12 to <15 years old) adolescents compared to older (15 to <18 years old) adolescents. No new safety signal was observed through the placebo-controlled portion of the pediatric expansion.

• Yesterday, New Zealand granted expanded use approval for the shot as a heterologous and homologous booster dose in adults.

• Price Action: NVAX shares are down 4.11% at $37.75 on the last check Thursday.

• Image by torstensimon from Pixabay

See more from Benzinga

• Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022

• Novavax Seeks FDA Emergency Use Nod For Its COVID-19 Vaccine Booster

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.